Production (Stage)
D
Scienture Holdings, Inc. SCNX
$0.8764 -$0.0136-1.53% NASDAQ
Recommendation
Prev Close
$0.8764
Volume
62,368
Avg Vol (90D)
1,982,278
Market Cap
$11.50M
Dividend & Yield
--
52-Week Range
$0.69 - $13.42
P/E (TTM)
--
EPS (TTM)
-$2.50
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
SCIENTURE Announces Executive Leadership Transition
5/22/2025 - Globe Newswire
SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.
5/19/2025 - Globe Newswire
Scienture Holdings Divests Subsidiaries to Tollo Health
4/11/2025 - TipRanks Financial Blog
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.
4/8/2025 - Globe Newswire
Scienture Holdings, Inc. Issues Annual Letter to Shareholders
4/3/2025 - GuruFocus
Scienture Holdings, Inc. Issues Annual Letter to Shareholders
4/3/2025 - Globe Newswire
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
3/25/2025 - Globe Newswire
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching ...
3/19/2025 - GuruFocus
Scienture Holdings announces draw on Equity Line of Credit
3/19/2025 - Seeking Alpha - Healthcare
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
3/19/2025 - Globe Newswire
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
3/18/2025 - Globe Newswire
SCIENTURE to commercially launch REZENOPY , a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
3/6/2025 - Globe Newswire
Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual ...
1/21/2025 - GuruFocus
Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics
1/21/2025 - Globe Newswire
Scienture Holdings Board Restructures After Director Resignations
1/17/2025 - TipRanks Financial Blog
Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
12/17/2024 - GuruFocus
Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
12/17/2024 - Globe Newswire
Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
12/10/2024 - Globe Newswire
Scienture Holdings files for secondary stock offering
12/4/2024 - SeekingAlpha.com: All News
Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement
11/26/2024 - Globe Newswire
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to SCNX
9/24/2024 - Globe Newswire
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.
9/20/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$106.36M
Total Debt (Q)
$3.81M
Total Liabilities (Q)
$25.20M
Book Value Per Share (Q)
$6.49
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Monday, May 12, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Sep 22 and 26 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-2.61%
30-Day Total Return
12.10%
60-Day Total Return
-66.93%
90-Day Total Return
-79.18%
Year to Date Total Return
-85.40%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $0.69
52-week High
Jul 29, 2024 - $13.42
Valuation
Market Cap
$11.50M - Nano Cap
Enterprise Value
$13.26M
Price/Sales (TTM)
64.44
Price/Book (Q)
0.14
Dividends and Shares
Shares Outstanding
9.43M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
scienture.com
Phone Number
800 261 0281
Address
6308 Benjamin Rd
Tampa, FL 33634
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Health Care Equipment and Services
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed